Healthcare startup doc.ai has launched the Epilepsy Digital Health Trial to improve treatment options for the condition and to test how artificial intelligence (AI) can help create a predictive and accurate treatment for curing diseases.
doc.ai has collaborated with the Stanford University School of Medicine and the Stanford Epilepsy Center to deploy and test AI to develop a predictive treatment model.
Epilepsy is a neurological disorder characterised by recurrent seizures. It affects approximately 65 million people worldwide and 3.4 million in the US.
doc.ai CEO De Brouwer said: “We’re testing our AI capabilities to help clinicians and their patients to find the optimal anti-seizure drug for an individual.
“Utilising AI and real-world data from multiple sources for medical research is a step forward in medicine. It has the potential to reduce costs and increase participation by reaching users on the devices they use every day.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The Epilepsy Digital Health Trial is an at-home, HIPAA-compliant and IRB-approved trial seeking to enrol up to 1,000 eligible participants from September 2019 to September 2020.
Patients will be enrolled through the doc.ai app.
They will keep an online diary to track their seizure episodes and medication side effects for up to three months.
The study will also gather and analyse patients’ health data, including personal-omics information such as the genome (DNA test provided by Kailos) and the phenome to capture physical traits.
It will also analyse patients’ physiome for exercise and activity tracking, pharmacome or medication tracking, and the exposome.
The digital health trial leverages doc.ai AI technologies, which includes natural language processing for automatic import of medical bottled photographs captured by the participants.
Kailos Genetics chief scientific officer Troy Moore said: “doc.ai has a robust multi-omics data pipeline, and we’re proud to contribute DNA tests free of charge to advance medicine.”
Upon completion of the trial, participants will receive an individualised report of gathered data to share with their physicians.
The Epilepsy Digital Health Trial is now open for enrolment for the US patients aged between 18 and 100 years, who are identified with epilepsy and have a smartphone using the iOS operating system.
doc.ai also has two other digital health trials open to improve the precision in treatment of inflammatory bowel disease and allergies.